CSIMarket
 
Perspective Therapeutics Inc   (CATX)
Other Ticker:  
 
 

Perspective Therapeutics Inc's Customers Performance

CATX

 
CATX's Source of Revenues

List of CATX Customers




for the same period Perspective Therapeutics Inc

List of CATX Customers





Perspective Therapeutics Inc's Comment on Sales, Marketing and Customers





  News about Perspective Therapeutics Inc Contracts

Perspective Therapeutics Joins Russell 3000 Index, Presents at SNMMI 2024, and Raises $80 Million in Underwritten Off...

'Perspective Therapeutics Joins the Russell 3000 Index and Showcases Innovation at SNMMI Annual Meeting Amid Successful $80 Million Offering''SEATTLE, June 12, 2024' ?? Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatment applications for cancers throughout the body, has announced its inclusion in the broad-market Russell 3000 Index. This significant milestone will take effect at the opening of U.S. equity markets on Monday, July 1, 2024, following the conclusion of the 2024 Russell US Indexes annual reconstitution. The final update, including Perspective Therapeutics among the additions, was confirmed on June 10, 2024.Joining the Russell 3000 Inde...

Perspective Therapeutics Implements Reverse Stock Split to Enhance Shareholder Value

In a significant move aimed at optimizing shareholder value, Perspective Therapeutics, Inc. (CATX), a pioneering radiopharmaceutical company specializing in advanced cancer treatment applications, recently announced its plans for a 1-for-10 reverse stock split. This strategic decision, effective from June 14, 2024, marks a crucial milestone for Perspective as it prepares to list its common stock on the NYSE American exchange under the existing trading symbol CATX.Enhancing Market Position:The reverse stock split, facilitated by Perspective Therapeutics, is expected to position the company favorably in the market. By reducing the number of outstanding shares, this move will enhance the stock's value per share...

Breaking Barriers: Perspective Therapeutics Shines at Radiopharmaceutical Conference

Perspective Therapeutics Makes Waves at Radiopharmaceutical ConferencePerspective Therapeutics, a leading radiopharmaceutical company, showcased its cutting-edge alpha-particle radiopharmaceuticals at the SNMMI 2024 Annual Meeting. The Company a...

Perspective Therapeutics' Leadership Team Set to Engage with Investors at Upcoming May Conferences

Seattle-based Perspective Therapeutics, Inc. has announced that its senior leadership team is set to participate in several investor conferences slated for May. The radiopharmaceutical company, a player in the medical industry pioneering advanced treatment avenues for various forms of cancer, disseminated this information in a statement on May 3, 2024.This participation is an opportunity for Perspective Therapeutics to interact with the investor community. The company (NYSE AMERICAN: CATX) offers advanced treatments applying radiopharmaceutical techniques for diverse cancer forms. It is robustly maturing its offerings to cater to the rising demand for new-age, effective, and targeted therapies for cancer pat...

Perspective Therapeutics Set to Report Strong Financial Results and Showcase Progress in Pioneering Cancer Treatments

Perspective Therapeutics, a pioneering radiopharmaceutical company specializing in advanced cancer treatments, is set to provide an update on its recent business highlights and report its first quarter 2024 financial results on May 15, 2024. This announcement comes after the company successfully closed a public offering, raising approximately $69.0 million in gross proceeds.The closing of the underwritten public offering saw Perspective Therapeutics offer 156,399,542 shares of its common stock at a price of $0.37 per share. This figure includes the exercise of the underwriters' option to purchase an additional 24,324,324 shares. In addition to common stock, certain investors were also given pre-funded warran...












CATX's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Perspective Therapeutics Inc 2,760.39 -1,959.66 2.65 -
SUBTOTAL 0.00 0.00 0.00 -


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com